更新
4月17日 - ** 制药商礼来LLY.N股价盘前上涨11.3%至817.99美元
** 该公司称其口服药物orforglipron在一项后期试验中使2型糖尿病超重患者的体重平均减轻了7.9% (link)，并降低了血糖。
** 礼来的肥胖症药物竞争对手诺和诺德NOVOb.CO在美国上市的股票下跌3.8%。
** 其他减肥药开发商，如 Viking Therapeutics VKTX.O 下跌 4.6%，Amgen AMGN.O 下跌 2
** 截至收盘，LLY 股价下跌 4.8%，VKTX 今年下跌 41.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.